CI vs JNJ
CI: A diversified global health services organization providing integrated pharmacy benefits and comprehensive health insurance solutions. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | CI | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $277.51 | $270.24 | |
| Market cap as of 2026-08-24 | $73.3B | $651.3B | |
| P/E as of 2026-08-24 | 11.52 | 29.93 | CI lower |
| PEG as of 2026-08-24 | 1.53 | 3.39 | CI lower |
| Net margin as of 2026-08-24 | +2.3% | +21.5% | JNJ higher |
| Gross margin as of 2026-08-24 | +9.1% | +68.0% | JNJ higher |
| Operating margin as of 2026-08-24 | +3.5% | +25.7% | JNJ higher |
| ROE as of 2026-08-24 | +15.2% | +25.7% | JNJ higher |
| ROA as of 2026-08-24 | +4.1% | +10.6% | JNJ higher |
| Debt / equity as of 2026-08-24 | 0.75 | 0.58 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-24 | +7.8% | +8.1% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +15.0% | +6.2% | CI higher |
| Dividend yield as of 2026-08-24 | +1.7% | +3.1% | JNJ higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.29 | 0.20 | |
| 1-year return as of 2026-08-21 close | -7.8% | +51.0% | JNJ higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.